Yayın:
TREATMENT OF STEROID-RESISTANT RENAL-ALLOGRAFT REJECTION WITH OKT-3 AND PLASMAPHERESIS

Basit öğe sayfası
dc.contributor.authorHABERAL, M
dc.contributor.authorBULUT, O
dc.contributor.authorSERT, S
dc.contributor.authorGULAY, H
dc.contributor.authorARSLAN, G
dc.contributor.authorGUNGEN, Y
dc.contributor.authorHAMALOGLU, E
dc.contributor.authorALTUNKAN, S
dc.contributor.authorBILGIN, N
dc.date.accessioned2026-06-27T12:57:51Z
dc.date.issued1991
dc.description.abstractThe murine monoclonal antibody (OKT-3) and plasmapheresis therapy were applied in combination to treat acute renal allograft rejection in 31 patients who were not responsive to conventional bolus steroid treatment. Six of them were living related but ABO incompatible; another 25 patients were ABO compatible (1 was from a cadaver, 7 were from living unrelated donors, and 17 were from living related donors). Of these 31 patients, 25 (80.65%) showed perfect improvement in their graft function. These 25 patients had a mean follow-up time of 8 months, and had mean creatinine values of 1.2 mg % (0.8-2.8 mg %). It is concluded that OKT-3 and plasmapheresis combination therapy is very effective in reversing steroid-resistant rejections in high-risk patients such as ABO-incompatible cases.en
dc.description.urihttps://doi.org/10.3109/08860229109022146
dc.identifier.doi10.3109/08860229109022146
dc.identifier.endpage47
dc.identifier.issn0886-022X
dc.identifier.issue1
dc.identifier.pubmed1924915
dc.identifier.startpage43
dc.identifier.urihttps://hdl.handle.net/20.500.14981/48245
dc.identifier.volume13
dc.identifier.wosA1991GA89200008
dc.language.isoeng
dc.publisherMARCEL DEKKER INC
dc.relation.ispartofRENAL FAILURE
dc.subjectOKT3
dc.subjectPLASMAPHERESIS, REJECTION
dc.subjectRENAL TRANSPLANTATION
dc.subjectUrology & Nephrology
dc.titleTREATMENT OF STEROID-RESISTANT RENAL-ALLOGRAFT REJECTION WITH OKT-3 AND PLASMAPHERESIS
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar

Yayınlar